Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Lanxess Deutschland Gmbh

Bayer Healthcare Aktiengesellschaft

Johns Hopkins University

Hartmut Schirok

Karl-Heinz Schlemmer

Stefan Heitmeier

Adrian Tersteegen

Christoph Gerdes

Johannes-Peter Stasch

Dieter Lang

Joachim Mittendorf

Anja Buchmüller

Ulf Bömer

Alexander Hillisch

Susanne Röhrig

Martina Schäfer

Mario Lobell

Henrik Teller

Gerhard Siemeister

Hans Briem

Klaus Münter

Frank Wunder

Philip Lienau

Dirk Kosemund

Benjamin Bader

Antje Margret Wengner

Raimund Kast

Mark Jean Gnoth

Volker Schulze

Niels Lindner

Marcus Koppitz

Marcus Bauser

Simon Holton

Pierre Wasnaire

Walter Hubsch

Klemens Lustig

Nils Griebenow

Lars Bärfacker

Walter Hübsch

Achim Feurer

Heike Heckroth

Duy Nguyen

Anne Mengel

Joerg Keldenich

Friederike Stoll

Chantal Fürstner

Cristina Alonso-Alija

Tobias Marquardt

Jürgen Klar

Martina Victoria Schmidt

Eloisa Jimenez Nunez

Julia Strassburger

Georges Von Degenfeld

Tom Kinzel

Samir Bennabi

Julia Straβburger

Heimo Ehmke

Ulrich Rester

Swen Allerheiligen

Stefan Prechtl

Martin Radtke

Santiago Figueroa Perez

Joachim Telser

Mary F Fitzgerald

Jens Hoffmann

Michael Härter

Kirstin Petersen

Olaf Prien

Detlef Stöckigt

Carsten Terjung

Dirk Brohm

Elke Dittrich-Wengenroth

Stephan Siegel

Kersten Matthias Gericke

Wolfgang Ebenbeck

Arne Von Bonin

Cynthia Ann Berlinicke

Herbert Himmel

Susanne Rohrig

Marie-Pierre Collin

Derek Stuart Welsbie

Michael Thutewohl

Hannah Jörißen

Sylvia Grünewald

Oliver Von Ahsen

Juergen Klar

Martin Michels

Martina Schaefer

Julia Straßburger

Michael Böttger

Thomas Schlange

Mélanie Héroult

Verena Voehringer

Melanie Heroult

Jean Mark Gnoth

Uwe Saatman

Uwe Saatmann

Andreas Schall

Hanna Eilken

Dmitrij Hristodorov

Ying Li-Sommer

Michael Brands

Matthias Renz

The invention relates to 5-({6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1(2H)-yl]-3-methylhexanoyl}amino)pyrazolo[1,5-a]pyridine-3-carboxamide to processes for its preparation, to its use for the treatment and/or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and edemas, and also ophthalmic disorders, and its use to inhibit disturbing plasma kallikrein activity for the conduct of extracorporeal procedures and analytical assays.

Substituted oxopyridine derivative

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Substituted oxopyridine derivatives and use thereof cardiovascular disorders

The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Substituted oxopyridine derivatives

The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Substituted pyridobenzodiazepinone-derivatives and use thereof

Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders

The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors: Formula (I), in which R, R, R, R, and Rare as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis proliferative of diseases, as well as to intermediate compounds useful in the preparation of said compounds. 

Triazolopyridines

The present invention relates to substituted triazolopyridine compounds of general formula (I); in which R, R, R, R, and Rare as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds. 

Substituted triazolopyridines

The present invention relates to substituted triazolopyridine compounds of general formula (I): in which R, R, R, R, and Rare as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease of uncontrolled cell growth, proliferation and/or survival as well as to the use of intermediate compounds for the preparation of said compounds. 

This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.

Substituted benzothienyl-pyrrolotriazines and uses thereof

This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.

Substituted tricyclic compounds and methods of use thereof

The invention relates to novel substituted oxazolidinones, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.

Substituted oxazolidinones and their use

The present application relates to novel aliphatically substituted pyrazolopyridines, to processes for their preparation, to their use, alone or in combination, for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.

Aliphatically substituted pyrazolopyridines, and the use thereof

The invention relates to hetaryloxy-substituted phenylaminopyrimidines, to a process for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases in humans and animals, in particular cardiovascular disorders.

Hetaryloxy-substituted phenylamino pyrimidines as Rho kinase inhibitors

Growing community of inventors

Langenfeld, Germany

Hartmut Schirok